Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Issue 8 (20th March 2017)

• Record Type: Journal Article
• Authors: Winchester, Danyelle A.; Till, Cathee; Goodman, Phyllis J.; Tangen, Catherine M.; Santella, Regina M.; Johnson‐Pais, Teresa L.; Leach, Robin J.; Xu, Jianfeng; Zheng, S. Lilly; Thompson, Ian M.; Lucia, M. Scott; Lippman, Scott M.; Parnes, Howard L.; Isaacs, William B.; De Marzo, Angelo M.; Drake, Charles G.; Platz, Elizabeth A.
• Is Part Of: Prostate. Volume 77:Issue 8(2017)
• Page Start: 908
• Page End: 919
• Publication Date: 2017-03-20
• Subjects: finasteride -- immune genes -- prostate cancer -- SNPs; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23346
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: BACKGROUND: We reported that some, but not all single nucleotide polymorphisms (SNPs) in select immune response genes are associated with prostate cancer, but not individually with the prevalence of intraprostatic inflammation in the Prostate Cancer Prevention Trial (PCPT) placebo arm. Here, we investigated whether these same SNPs are associated with risk of lower‐ and higher‐grade prostate cancer in men randomized to finasteride, and with prevalence of intraprostatic inflammation among controls. Methods A total of 16 candidate SNPs in IL1β, IL2, IL4, IL6, IL8, IL10, IL12(p40), IFNG, MSR1, RNASEL, TLR4, and TNFA and 7 tagSNPs in IL10 were genotyped in 625 white prostate cancer cases, and 532 white controls negative for cancer on an end‐of‐study biopsy nested in the PCPT finasteride arm. We used logistic regression to estimate log‐additive odds ratios (OR) and 95% confidence intervals (CI) adjusting for age and family history. RESULTS: Minor alleles of rs2243250 (T) in IL4 (OR = 1.46, 95% CI 1.03‐2.08, P‐trend = 0.03), rs1800896 (G) in IL10 (OR = 0.77, 95% CI 0.61‐0.96, P‐trend = 0.02), rs2430561 (A) in IFNG (OR = 1.33, 95% CI 1.02‐1.74; P‐trend = 0.04), rs3747531 (C) in MSR1 (OR = 0.55, 95% CI 0.32‐0.95; P‐trend = 0.03), and possibly rs4073 (A) in IL8 (OR = 0.81, 95% CI 0.64‐1.01, P‐trend = 0.06) were associated with higher‐ (Gleason 7‐10; N = 222), but not lower‐ (Gleason 2‐6; N = 380) grade prostate cancer. In men with low PSA (<2 ng/mL), these higher‐grade disease associations were attenuated and/or no longer significant, whereas associations with higher‐grade disease were apparent for minor alleles of rs1800795 (C: OR = 0.70, 95% CI 0.51‐0.94, P‐trend = 0.02) and rs1800797 (A: OR = 0.72, 95% CI 0.53‐0.98, P‐trend = 0.04) in IL6 . While some IL10 tagSNPs were associated with lower‐ and higher‐grade prostate cancer, distributions of IL10 haplotypes did not differ, except possibly between higher‐grade cases and controls among those with low PSA ( P = 0.07). We did not observe an association between the studied SNPs and intraprostatic inflammation in the controls. CONCLUSION: In the PCPT finasteride arm, variation in genes involved in the immune response, including possibly IL8 and IL10 as in the placebo arm, may be associated with prostate cancer, especially higher‐grade disease, but not with intraprostatic inflammation. We cannot rule out PSA‐associated detection bias or chance due to multiple testing.